- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-07-10
DOI
10.1038/s41585-018-0055-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
- (2017) Sebastien Antoni et al. EUROPEAN UROLOGY
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
- (2017) Marko Babjuk et al. EUROPEAN UROLOGY
- Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
- (2017) Roland Seiler et al. EUROPEAN UROLOGY
- Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
- (2017) Neal D. Shore et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis
- (2017) Brock E. Boehm et al. JOURNAL OF UROLOGY
- Immunotherapy for the Treatment of Urothelial Carcinoma
- (2017) Nicholas M. Donin et al. JOURNAL OF UROLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG
- (2017) Ashish M. Kamat et al. Nature Reviews Urology
- Ensuring Access to Injectable Generic Drugs — The Case of Intravesical BCG for Bladder Cancer
- (2017) Benjamin J. Davies et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non–muscle-invasive bladder cancer
- (2017) Ryan L. Steinberg et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Bladder cancer
- (2017) Oner Sanli et al. Nature Reviews Disease Primers
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Molecular Subtypes of Non-muscle Invasive Bladder Cancer
- (2016) Seth P. Lerner et al. CANCER CELL
- Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
- (2016) Jakob Hedegaard et al. CANCER CELL
- Novel therapeutic targets in advanced urothelial carcinoma
- (2016) Mathieu Rouanne et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
- (2016) Ashish M. Kamat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Innovation in Bladder Cancer Immunotherapy
- (2016) H. Barton Grossman et al. JOURNAL OF IMMUNOTHERAPY
- Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer
- (2016) Akira Yokomizo et al. JOURNAL OF UROLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
- (2016) Maria I. Carlo et al. Nature Reviews Urology
- Recommandations en onco-urologie 2016-2018 du CCAFU : Tumeurs de la vessie
- (2016) M. Rouprêt et al. PROGRES EN UROLOGIE
- The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer
- (2016) J. Alfred Witjes et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer
- (2016) Renate Pichler et al. Oncotarget
- Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor
- (2016) A. J. Vandeveer et al. Cancer Immunology Research
- A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
- (2015) Edgardo D. Carosella et al. EUROPEAN UROLOGY
- Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
- (2015) Ashish M. Kamat et al. Nature Reviews Urology
- Macrophages Subvert Adaptive Immunity to Urinary Tract Infection
- (2015) Gabriela Mora-Bau et al. PLoS Pathogens
- Bacillus Calmette-Guérin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy
- (2014) Cyrill A. Rentsch et al. EUROPEAN UROLOGY
- All Bacillus Calmette-Guérin (BCG) Strains Are Equal, but Some BCG Strains Are More Equal Than Others
- (2014) Aidan P. Noon et al. EUROPEAN UROLOGY
- Bacillus Calmette-Guérin (BCG) Infection Following Intravesical BCG Administration as Adjunctive Therapy For Bladder Cancer
- (2014) María Asunción Pérez-Jacoiste Asín et al. MEDICINE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
- (2014) J. S. Damrauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recommandations en onco-urologie 2013 du CCAFU : Tumeurs de la vessie
- (2014) C. Pfister et al. PROGRES EN UROLOGIE
- Disseminated infection due toMycobacterium bovisafter intravesical BCG instillation
- (2014) Sara Marquez-Batalla World Journal of Clinical Cases
- Toward a Molecular Pathologic Classification of Urothelial Carcinoma
- (2013) Gottfrid Sjödahl et al. AMERICAN JOURNAL OF PATHOLOGY
- Prognostic value of inflammation or granuloma after intravesival BCG in non-muscle-invasive bladder cancer
- (2013) Samer Jallad et al. BJU INTERNATIONAL
- Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells
- (2013) G. Redelman-Sidi et al. CANCER RESEARCH
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
- (2013) Maurizio Brausi et al. EUROPEAN UROLOGY
- A Prospective Comparative Study of Intravesical Bacillus Calmette-Guérin Therapy with the Tokyo or Connaught Strain for Nonmuscle Invasive Bladder Cancer
- (2013) Atsushi Sengiku et al. JOURNAL OF UROLOGY
- From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa
- (2013) M A Ingersoll et al. Mucosal Immunology
- Interferon alfa in the treatment paradigm for non–muscle-invasive bladder cancer
- (2013) Donald Lamm et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The Effect of Fibrin Clot Inhibitors on the Immunomodulatory Efficacy of Bacillus Calmette-Guérin Therapy for Non–muscle-invasive Bladder Cancer
- (2013) Michael J. Lipsky et al. UROLOGY
- A Molecular Taxonomy for Urothelial Carcinoma
- (2012) G. Sjodahl et al. CLINICAL CANCER RESEARCH
- Re: Preexisting BCG-specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
- (2012) Edward M. Messing EUROPEAN UROLOGY
- Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance
- (2012) Jorg Oddens et al. EUROPEAN UROLOGY
- Connaught and Russian Strains Showed the Highest Direct Antitumor Effects of Different Bacillus Calmette-Guérin Substrains
- (2012) Silvia Secanella-Fandos et al. JOURNAL OF UROLOGY
- Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
- (2012) C. Biot et al. Science Translational Medicine
- Blocking IL-10 enhances bacillus Calmette-Guérin induced T helper Type 1 immune responses and anti-bladder cancer immunity
- (2012) Yi Luo OncoImmunology
- Markers Predicting Response to Bacillus Calmette-Guérin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review
- (2011) Tahlita C.M. Zuiverloon et al. EUROPEAN UROLOGY
- Editorial: Neutrophil apoptosis: hot on the TRAIL of inflammatory resolution
- (2011) Andrew E. Leitch et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Macrophages and control of granulomatous inflammation in tuberculosis
- (2011) J L Flynn et al. Mucosal Immunology
- Biochemical characteristics amongMycobacterium bovisBCG substrains
- (2010) Daisuke Hayashi et al. FEMS MICROBIOLOGY LETTERS
- Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer
- (2010) Richard J Sylvester INTERNATIONAL JOURNAL OF UROLOGY
- Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer
- (2010) Kenneth G. Nepple et al. JOURNAL OF UROLOGY
- The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette–Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder
- (2009) Henry M. Rosevear et al. CANCER AND METASTASIS REVIEWS
- Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
- (2009) Richard J. Sylvester et al. EUROPEAN UROLOGY
- Bacillus Calmette–Guerin immunotherapy for urothelial carcinoma of the bladder
- (2009) Timothy P Kresowik et al. Immunotherapy
- Fibrin Clot Inhibitor Medication and Efficacy of Bacillus Calmette-Guerin for Bladder Urothelial Cancer
- (2009) Stephen A. Boorjian et al. JOURNAL OF UROLOGY
- Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer
- (2009) Aurélie Bisiaux et al. JOURNAL OF UROLOGY
- Phenotypic differences between BCG vaccines at the proteome level
- (2009) Mauricio Rodríguez-Alvarez et al. TUBERCULOSIS
- Optimizing BCG therapy
- (2009) Michael A. O'Donnell UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Role of neutrophils in BCG immunotherapy for bladder cancer
- (2008) Mark P. Simons et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success Story
- (2007) Harry W. Herr et al. JOURNAL OF UROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now